FDA Approves Fulyzaqâ„¢ (Crofelemer) 125 mg Delayed-Release Tablets For The Symptomatic Relief Of Diarrhea In Patients With HIV/AIDS On Anti-Retroviral Therapy (ART)

[at noodls] – Fulyzaqâ„¢ Offers a Unique Treatment for ART-Related Diarrhea in HIV Positive Patients RALEIGH, NC, January 2, 2013 – Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration … more

View todays social media effects on SLXP

View the latest stocks trending across Twitter. Click to view dashboard

See who Salix is hiring next, click here to view